The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge
Tongwei Zeng,Yongqiang Xie,Keqiang Chai,Hui Sang
DOI: https://doi.org/10.2147/ott.s485869
IF: 4
2024-11-17
OncoTargets and Therapy
Abstract:Tongwei Zeng, &ast Yongqiang Xie, &ast Keqiang Chai, Hui Sang Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, 730900, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hui Sang; Keqiang Chai, Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, No. 222, Silong Road, Baiyin District, Baiyin City, Gansu Province, People's Republic of China, Email ; In recent years, the incidence of prostate cancer has been increasing globally. Early stage of the disease can obtain a better clinical prognosis from surgery and endocrine therapy. The progression of advanced stage varies significantly between individuals, with some patients developing metastatic castration-resistant prostate cancer after standardized treatment. Therefore, staging of prostate cancer by accurate imaging is particularly important for the clinical management of patients. Simultaneously, the development of targeted therapy is also urgent for the treatment of advanced prostate cancer. Prostate specific membrane antigen as a prostate specific target has been widely used in the diagnosis and treatment of prostate cancer. This review summarizes the latest research progress of targeted prostate specific membrane antigen in the diagnosis and treatment of prostate cancer in detail, analyzes their value and challenges. Keywords: prostate cancer, PSMA, PET, radioligand therapy, CAR-T, DCs vaccine Prostate cancer (PCa) is the second most common malignancy in men worldwide and the most diagnosed cancer in European countries. 1 The United States reported 268,490 new cases and 34,500 deaths in 2022. 2 Because of the long course of PCa and the variation in clinical progress between individual patients, 3,4 clinicians tend to view the diagnosis and treatment of PCa as a lengthy process. 5 If PCa is diagnosed at an early stage, the life expectancy of the patients can be more than 10 years, up to 99%. 6 However, for some other patients, recurrent PCa after standard treatment may be aggressive and may not respond to current standard treatment under certain circumstances. About 5% of patients with PCa are clinically diagnosed with distant metastases, of which 15% are diagnosed with local regional metastasis. 7 If the disease progresses to advanced PCa, the 5-year overall survival rate is only 30%. 7 Therefore, the selection of the most appropriate diagnostic strategy for accurate staging of the disease has a crucial role in guiding the management of PCa patients. Furthermore, the implementation of targeted therapeutic approaches for the management of recurrent PCa holds significant significance. Currently, prostate-specific antigen (PSA) is used as a preliminary screening indicator for PCa, and further testing will be performed for patients with abnormal PSA values. In recent years, studies have confirmed that PSA screening is clear in reducing the specific mortality of PCa. 8 Gleason score is used to determine the degree of aggressiveness of PCa by pathological methods, and can predict the prognosis of PCa patients. 9 The multi-parameter magnetic resonance imaging (mpMRI) is recommended for local staging in moderate-high risk patients. 10 Computed tomography (CT) and bone scan (BS) for cross-sectional abdominal and pelvic imaging is recommended for the assessment of distant metastasis. 11 As an alternative to conventional PCa imaging, molecular imaging is increasingly used to guide treatment decisions in PCa patients in recent years. 12 Furthermore, the development of specific targeted therapies for PCa can benefit many patients with advanced PCa. As a diagnostic and therapeutic target for PCa, prostate specific membrane antigen (PSMA) has gained considerable attention. It can be used for positron emitter labeling for positron emission tomography (PET) imaging, as well as β and α emitter labeling for targeted radionuclide therapy. 13 In addition, due to its specific expression and internalization in PCa, PSMA can be used in tumor immunotherapy and carry drugs to kill tumors. PSMA, also known as glutamate carboxypeptidase II, is a transmembrane protein composed of 750 amino acids, which is a membrane protein on the cell surface. 14,15 PSMA protein is divided into three parts, namely intracellular part, transmembrane part and extracellular part. 16,17 The extracellular portion makes up 95% of the PSMA protein and is the target portion accessible to small molecule and antibody drugs for imaging and therapy. Cell surface PSMA receptor binding proteins can migrate PSMA labeled radioisotopes into cells through internal -Abstract Truncated-
oncology,biotechnology & applied microbiology